SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kuo-Hsin Chen, Chih-Yuan Lee, Fe-Lin Lin Wu, Ching-Yao Yang, Chi-Chuan Yeh, Rey-Heng Hu, Meng-Kun Tsai, De novo cancer avoidance after renal transplantation: A case–control study on low-dose sirolimus combined with a calcineurin inhibitor, Journal of the Formosan Medical Association, 2015,

    CrossRef

  2. 2
    Ji-Won Jung, Nana H. Overgaard, Michael T. Burke, Nicole Isbel, Ian H. Frazer, Fiona Simpson, James W. Wells, Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?, International Journal of Cancer, 2015, 137, 3
  3. 3
    Marina Zoega Hayashida, Victor Miguel Coutinho Fernandes, Diana Rosa de Melo Fernandes, Marília Marufuji Ogawa, Jane Tomimori, Epidemiology and clinical evolution of non-melanoma skin cancer in renal transplant recipients: a single-center experience in São Paulo, Brazil, International Journal of Dermatology, 2015, 54, 5
  4. 4
    Michael T Burke, Nicole Isbel, Katherine A Barraclough, Ji-Won Jung, James W Wells, Christine E Staatz, Genetics and nonmelanoma skin cancer in kidney transplant recipients, Pharmacogenomics, 2015, 16, 2, 161

    CrossRef

  5. 5
    Atsushi Otsuka, Mitchell P. Levesque, Reinhard Dummer, Kenji Kabashima, Hedgehog signaling in basal cell carcinoma, Journal of Dermatological Science, 2015, 78, 2, 95

    CrossRef

  6. 6
    Renaud Snanoudj, Claire Tinel, Christophe Legendre, Immunological risks of minimization strategies, Transplant International, 2015, 28, 6
  7. 7
    Christophe Duvoux, Christian Toso, mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?, Transplantation Reviews, 2015,

    CrossRef

  8. 8
    E. L. Yanik, S. K. Gustafson, B. L. Kasiske, A. K. Israni, J. J. Snyder, G. P. Hess, E. A. Engels, D. L. Segev, Sirolimus Use and Cancer Incidence Among US Kidney Transplant Recipients, American Journal of Transplantation, 2015, 15, 1
  9. 9
    Edward K Geissler, Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?, Transplantation Research, 2015, 4, 1

    CrossRef

  10. 10
    Steven J. Chadban, Josette Marie Eris, John Kanellis, Helen Pilmore, Po Chang Lee, Soo Kun Lim, Chad Woodcock, Nicol Kurstjens, Graeme Russ, A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients, Transplant International, 2014, 27, 3
  11. 11
    Nazanin Majd, Kazutaka Sumita, Hirofumi Yoshino, Dillon Chen, Jumpei Terakawa, Takiko Daikoku, Satoshi Kofuji, Richard Curry, Trisha M. Wise-Draper, Ronald E. Warnick, Jessica Guarnaschelli, Atsuo T. Sasaki, A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic, Journal of Cancer Research, 2014, 2014, 1

    CrossRef

  12. 12
    W. H. Lim, J. Eris, J. Kanellis, B. Pussell, Z. Wiid, D. Witcombe, G. R. Russ, A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients, American Journal of Transplantation, 2014, 14, 9
  13. 13
    Nolwenn Rabot, Matthias Büchler, Yohann Foucher, Anne Moreau, Celine Debiais, Marie-Christine Machet, Michelle Kessler, Emmanuel Morelon, Antoine Thierry, Christophe Legendre, Joseph Rivalan, Nassim Kamar, Jacques Dantal, CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality, Transplant International, 2014, 27, 9
  14. 14
    R. Salido-Vallejo, G. Garnacho-Saucedo, J.C. Moreno-Giménez, Current Options for the Treatment of Facial Angiofibromas, Actas Dermo-Sifiliográficas (English Edition), 2014, 105, 6, 558

    CrossRef

  15. 15
    Meteb AlBugami, Bryce Kiberd, Malignancies: Pre and post transplantation strategies, Transplantation Reviews, 2014, 28, 2, 76

    CrossRef

  16. 16
    Christopher D. Roche, Joelle S. Dobson, Sion K. Williams, Mara Quante, Joyce Popoola, Jade W. M. Chow, Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients, Dermatology Research and Practice, 2014, 2014, 1

    CrossRef

  17. 17
    Mareike Alter, Imke Satzger, Harald Schrem, Alexander Kaltenborn, Alexander Kapp, Ralf Gutzmer, Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2014, 12, 6
  18. 18
    R. Salido-Vallejo, G. Garnacho-Saucedo, J.C. Moreno-Giménez, Opciones terapéuticas actuales para los angiofibromas faciales, Actas Dermo-Sifiliográficas, 2014, 105, 6, 558

    CrossRef

  19. 19
    Georgi Tchernev, Uwe Wollina, Pathways of Tumor development and progression in Drug-induced Nonmelanoma Skin Cancer: a New Hope or the Next Great Confusion?, Wiener Medizinische Wochenschrift, 2014, 164, 13-14, 286

    CrossRef

  20. 20
    Mareike Alter, Imke Satzger, Harald Schrem, Alexander Kaltenborn, Alexander Kapp, Ralf Gutzmer, Rückgang nicht-melanozytärer Hauttumoren nach Umstellung der Immunsuppression auf mTOR-Inhibitoren bei organtransplantierten Patienten, JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2014, 12, 6
  21. 21
    A. Hanlon, O. R. Colegio, The Cutting Edge of Skin Cancer in Transplant Recipients: Scientific Retreat of International Transplant Skin Cancer Collaborative and Skin Cancer in Organ Transplant Patients Europe, American Journal of Transplantation, 2014, 14, 5
  22. 22
    Jacobien Verhave, Anne Boucher, Raymond Dandavino, Suzon Collette, Lynne Senécal, Marie-Josée Hebert, Catherine Girardin, Héloïse Cardinal, The incidence, management, and evolution of rapamycin-related side effects in kidney transplant recipients, Clinical Transplantation, 2014, 28, 5
  23. 23
    Goran B. Klintmalm, Sammy Saab, Johnny C. Hong, Björn Nashan, The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy, Clinical Transplantation, 2014, 28, 6
  24. 24
    Kassem Safa, Leonardo V. Riella, Anil Chandraker, Beyond calcineurin inhibitors, Current Opinion in Nephrology and Hypertension, 2013, 22, 6, 689

    CrossRef

  25. 25
    Robert P. Carroll, Jeremy R. Chapman, Can the Risk of Skin Cancer After Transplantation Be Reduced by mTOR Inhibitors?, American Journal of Kidney Diseases, 2013, 61, 5, 698

    CrossRef

  26. 26
    R. P. Carroll, J. Hester, K. J. Wood, P. N. Harden, Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype, Nephrology Dialysis Transplantation, 2013, 28, 2, 462

    CrossRef

  27. 27
    Massimiliano Veroux, Tiziano Tallarita, Daniela Corona, Antonino D’Assoro, Pierfrancesco Veroux, Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients, Expert Review of Anticancer Therapy, 2013, 13, 1, 17

    CrossRef

  28. 28
    Mikhail V Blagosklonny, Immunosuppressants in cancer prevention and therapy, OncoImmunology, 2013, 2, 12, e26961

    CrossRef

  29. 29
    P. J. O'Connell, D. J. Holmes-Walker, D. Goodman, W. J. Hawthorne, T. Loudovaris, J. E. Gunton, H. E. Thomas, S. T. Grey, C. J. Drogemuller, G. M. Ward, D. J. Torpy, P. T. Coates, T. W. Kay, Multicenter Australian Trial of Islet Transplantation: Improving Accessibility and Outcomes, American Journal of Transplantation, 2013, 13, 7
  30. 30
    F. Halleck, F. Friedersdorff, T.F. Fuller, M. Matz, L. Huber, M. Dürr, M. Schütz, K. Budde, New Perspectives of Immunosuppression, Transplantation Proceedings, 2013, 45, 3, 1224

    CrossRef

  31. 31
    Graeme R Russ, Optimising the use of mTOR inhibitors in renal transplantation, Transplantation Research, 2013, 2, Suppl 1, S4

    CrossRef

  32. 32
    L.J. Mackintosh, C.C. Geddes, R.M. Herd, Skin tumours in the West of Scotland renal transplant population, British Journal of Dermatology, 2013, 168, 5
  33. 33
    Jodi M. Smith, Karen Martz, Ruth A. McDonald, William E. Harmon, Solid tumors following kidney transplantation in children, Pediatric Transplantation, 2013, 17, 8
  34. 34
    M. Guba, J. Andrassy, M. Angele, C. Bruns, Tumor und Transplantation, Der Chirurg, 2013, 84, 8, 690

    CrossRef

  35. 35
    Hallvard Holdaas, Karsten Midtvedt, Anders Åsberg, A drug safety evaluation of everolimus in kidney transplantation, Expert Opinion on Drug Safety, 2012, 11, 6, 1013

    CrossRef

  36. 36
    Fabian Halleck, Michael Duerr, Johannes Waiser, Lu Huber, Mareen Matz, Susanne Brakemeier, Lutz Liefeldt, Hans-Hellmut Neumayer, Klemens Budde, An evaluation of sirolimus in renal transplantation, Expert Opinion on Drug Metabolism & Toxicology, 2012, 8, 10, 1337

    CrossRef

  37. 37
    Natasha Chandok, Kymberly D. Watt, Burden of de novo malignancy in the liver transplant recipient, Liver Transplantation, 2012, 18, 11
  38. 38
    Petter Gjersvik, Per Helsing, Hallvard Holdaas, Stein Bergan, Immunsuppressive legemidler og utvikling av hudkreft etter organtransplantasjon, Tidsskrift for Den norske legeforening, 2012, 132, 18, 2064

    CrossRef

  39. 39
    Maxime Touzot, Jean Paul Soulillou, Jacques Dantal, Mechanistic target of rapamycin inhibitors in solid organ transplantation, Current Opinion in Organ Transplantation, 2012, 17, 6, 626

    CrossRef

  40. 40
    G. Wong, J. R. Chapman, J. C. Craig, mTOR Inhibitors: A Myth, a Cure for Cancer or Something in Between?, American Journal of Transplantation, 2012, 12, 5
  41. 41
    Yu-Hong Gu, Jia-Xin Du, Man-Ling Ma, Sirolimus and Non-melanoma Skin Cancer Prevention after Kidney Transplantation: A Meta-analysis, Asian Pacific Journal of Cancer Prevention, 2012, 13, 9, 4335

    CrossRef

  42. 42
    Sylvie Euvrard, Emmanuel Morelon, Lionel Rostaing, Eric Goffin, Anabelle Brocard, Isabelle Tromme, Nilufer Broeders, Veronique del Marmol, Valérie Chatelet, Anne Dompmartin, Michèle Kessler, Andreas L. Serra, Günther F.L. Hofbauer, Claire Pouteil-Noble, Josep M. Campistol, Jean Kanitakis, Adeline S. Roux, Evelyne Decullier, Jacques Dantal, Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation, New England Journal of Medicine, 2012, 367, 4, 329

    CrossRef

  43. 43
    Fabian Halleck, Klemens Budde, Transplantation: Sirolimus for secondary SCC prevention in renal transplantation, Nature Reviews Nephrology, 2012, 8, 12, 687

    CrossRef

  44. 44
    A.M. James Shapiro, Camillo Ricordi, Long-term Outcomes after Islet Transplantation,